Dr Stephen Harrow is a consultant Clinical Oncologist. He completed a PhD combining radiation and viro-therapy in high grade glioma prior to completing his specialist clinical oncology training. Dr Harrow then undertook a fellowship in Radiation Oncology with the British Columbia Cancer Agency in Vancouver. There, he was involved in several research projects including initiating their Stereotactic Body Radiotherapy lung programme. He returned to the Beatson West of Scotland Cancer Centre in 2009 to take up a consultant position and then moved to the Edinburgh Cancer Centre in 2021.
At the Edinburgh Cancer Centre Dr Harrow delivers both radiotherapy and systemic anti-cancer therapy for thoracic malignancies and oligometastatic disease. He was awarded a National Research Scotland Fellowship from the Chief Scientists office which has allowed him dedicated research time to develop clinical and laboratory research projects. He is the lead clinician for Cancer Innovation and the Scottish Cancer Research Network (South East). He was the UK Chief Investigator for the pivotal SABR-COMET oligometastatic study and is UK lead for the subsequent oligometastatic studies, COMET-10 and COMET-3. He was awarded a 1.8 million pound grant from the Scottish Government to develop oligometastic SABR services across Scotland to ensure equity of access for Scottish patients and clinical trial development. His other research interests are in retreatment with radiotherapy, radiation induced pneumonitis, radiomics and drug/radiotherapy combinations (Concorde arm lead).